Etranacogene dezaparvovec(AMT-061)2b期研究:血友病B患者FIX活性正常或接近正常且出血停止
Etranacogene dezaparvovec是一种携带FIX Padua变体的AAV5载体基因疗法。2b期研究对3例重度至中重度血友病B成人单次静脉输注2×10^13基因组拷贝/kg,26周中期分析显示第6周平均FIX活性31%,第26周增至47%,出血完全停止且无需FIX替代,安全性良好。
要点
- 单次输注后FIX活性显著升高,26周时2例持续>40%。
- 26周内出血完全停止且无需FIX替代治疗。
- 即使存在低水平抗AAV5中和抗体,疗效仍一致。
核心结论
- Etranacogene dezaparvovec在重度至中重度血友病B患者中产生有临床意义的FIX活性升高,出血停止且无需FIX替代。
研究设计与样本
- 2b期研究,单次静脉输注2×10^13基因组拷贝/kg的etranacogene dezaparvovec,纳入3例重度至中重度血友病B成人,计划26周中期评估。
主要发现
- 第6周平均FIX活性为31%(23.9%-37.8%),第26周增至47%(33.2%-57.0%),2例受试者FIX活性持续>40%。
- 至26周出血完全停止,且无需FIX替代治疗。
- 总体耐受良好,未观察到肝酶或炎症标志物有临床意义升高,无需使用糖皮质激素。
关键数值与推荐
- 主要终点:单次给药后6周FIX活性≥5%。
- 第6周平均FIX活性31%(23.9%-37.8%),第26周47%(33.2%-57.0%)。
临床怎么用
- 支持在存在低水平抗AAV5中和抗体的重度至中重度血友病B患者中进一步评估该基因疗法。
局限性
- 样本量仅3例,为26周中期分析,长期安全性和疗效需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Etranacogene dezaparvovec (AMT-061) is a recombinant AAV5 vector including a gene cassette containing the factor IX (FIX) Padua variant under the control of a liver-specific promoter. A phase 2b study was conducted to confirm that a single dose of 2 × 1013 genome copies per kilogram of etranacogene dezaparvovec will result in FIX activity ≥5% 6 weeks after dosing. Secondary end points included FIX activity at other time points, bleed frequency, FIX replacement, and safety. Etranacogene dezaparvovec was administered as a single IV infusion to 3 adults with severe to moderately severe hemophilia B. Before treatment, participants had low levels of preexisting neutralizing antibodies to AAV5. This article reports a planned 26-week interim assessment. At week 6, mean FIX activity was 31% (23.9%-37.8%), increasing to 47% (33.2%-57.0%) at 26 weeks, with 2 subjects exhibiting sustained activity >40%. Consistent with the FIX activity, etranacogene dezaparvovec was associated with a complete bleed cessation with no need for FIX replacement therapy up to 26 weeks. Etranacogene dezaparvovec was generally well tolerated. No clinically significant elevations in levels of liver enzymes or inflammatory markers were observed, and no use of corticosteroids related to treatment was required. In individuals with severe to moderately severe hemophilia B, etranacogene dezaparvovec resulted in clinically relevant increases in FIX activity, cessation of bleeds, and abrogation of the need for FIX replacement, despite the presence of preexisting anti-AAV5 neutralizing antibodies detected by using a highly sensitive luciferase assay. Consistency of results in the 3 participants supported an expanded evaluation of the safety/efficacy of etranacogene dezaparvovec in the HOPE-B (Health Outcomes With Padua Gene; Evaluation in Hemophilia-B) phase 3 trial. The current trial was registered at www.clinicaltrials.gov as #NCT03489291.
引用
- Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019. PMID: 31698454. doi:10.1182/bloodadvances.2019000811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。